Palbociclib (PD0332991) - A selective and potent cyclin-dependent kinase inhibitor: A review of pharmacodynamics and clinical development

JAMA Oncology

Volumn 2, Issue 2, 2016, Pages 253-260

  Clark, Amy S ^a,b   Karasic, Thomas B ^b   DeMichele, Angela ^a,b,c   Vaughn, David J ^a,b   O'Hara, Mark ^a,b   Perini, Rodolfo ^a,b   Zhang, Paul ^b   Lal, Priti ^b   Feldman, Michael ^b   Gallagher, Maryann ^a   O'Dwyer, Peter J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Center for Clinical Epidemiology and Biostatistics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PALBOCICLIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85003047866     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4701     Document Type: Review

References (75)

1. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36(3):131-149.
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24(11):1770-1783.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
4. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33(15): 1890-1903.
5. Abramson VG, Troxel AB, Feldman M, et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 2010;30(4):1279-1285.
6. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009;16(2):36-43.
7. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 1997;15(11):3301-3312.
8. Ortega S, Malumbres M, BarbacidM. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602(1):73-87.
9. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378(2):F115-F177.
10. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3 (11):1427-1438.
11. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 1984;224(4656):1403-1406.
12. HallM, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67-108.
13. Malumbres M, BarbacidM. Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007;17(1):60-65.
14. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281-1284.
15. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67 (14):6626-6636.
16. Vaughn DJ, Flaherty K, Lal P, et al. Treatment of growing teratoma syndrome. N Engl J Med. 2009; 360(4):423-424.
17. Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17(6):1591-1602.
18. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
19. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010;70(8):3228-3238.
20. Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27(4): 590-600.
21. WiedemeyerWR, Dunn IF, Quayle SN, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010;107(25):11501-11506.
22. Cen L, Carlson BL, Schroeder MA, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012;14 (7):870-881.
23. Katsumi Y, Iehara T, Miyachi M, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun. 2011; 413(1):62-68.
24. Wainberg Z, Yufa A, Anghel A, et al. Expression of p16 in colon cancer and cyclin D1 in gastric cancer predicts response to CDK4/6 inhibition in vitro [abstract 4557]. Presented at the American Association of Cancer Research Annual Meeting 2014; April 8, 2014; San Diego, CA.
25. Rivadeneira DB, Mayhew CN, Thangavel C, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010;138(5):1920-1930.
26. Francis A, Carey JP, Alexander A, Keyomarsi K, Hunt KH. Targeting the RB-pathway in sarcoma: utility of CDK4/6 inhibitors [abstract 1327]. Presented at the American Association of Cancer Research Annual Meeting 2014; April 7, 2014; San Diego, CA.
27. Handschick K, Beuerlein K, Jurida L, et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. Mol Cell. 2014;53(2):193-208.
28. Abedin ZR, Ma Z, Reddy EP. Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle. 2010;9(12):2456-2463.
29. Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167-181.
30. Buss H, Handschick K, Jurrmann N, et al. Cyclin-dependent kinase 6 phosphorylates NF-κB P65 at serine 536 and contributes to the regulation of inflammatory gene expression. PLoS One. 2012; 7(12):e51847.
31. Thoms HC, Dunlop MG, Stark LA. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 2007;67(4):1660-1669.
32. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012; 287(34):29075-29087.
33. Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucosemetabolism independently of cell cycle progression. Nature. 2014;510(7506):547-551.
34. Zanuy M, Ramos-Montoya A, Villacanas O, et al. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics. 2012;8(3):454-464.
35. Rader J, RussellMR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173-6182.
36. Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20(5):620-634.
37. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10): 1503-1510.
38. Ziemke E, Dosch J, Shettigar A, et al. Dual targeting of CDK4 and MEK as a combination treatment strategy formetastatic colorectal cancer [abstract 4541]. Presented at the American Association of Cancer Research AnnualMeeting 2014; April 8, 2014; San Diego, CA.
39. Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136-149.
40. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res. 2002;8(9):2976-2984.
41. Luke JJ, D'Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res. 2012;18(9):2638-2647.
42. McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012; 11(14):2747-2755.
43. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012;104(6): 476-487.
44. Clark A, O'Dwyer P, Lal P, et al. A phase 1 trial of palbociclib and paclitaxel in breast cancer patients [abstract 527]. Presented at the American Association Society of Clinical Oncology Annual Meeting 2014; June 1, 2014; Chicago, IL.
45. Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 2013;12(12):1892-1900.
46. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MMmyeloma model. Cancer Res. 2008;68(14):5519-5523.
47. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primarymyeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66(15):7661-7667.
48. Kuo TC, Chavarria-Smith JE, Huang D, Schlissel MS. Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment. Mol Cell Biol. 2011; 31(13):2566-2576.
49. Comstock CE, Augello MA, Goodwin JF, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 2013;32(48): 5481-5491.
50. Liu F, Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012;11(10):2138-2148.
51. Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One. 2013;8(10): e77639.
52. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2): 568-576.
53. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011;104:1862-1868.
54. Perini RF, DeMichele A, Vaughn DJ, et al. Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. J Clin Oncol. 2011;29(15s):3088.
55. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597-4607.
56. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29: 1340-1347.
57. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31:1476-1489.
58. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013; 31(16):2024-2028.
59. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995;11 (5):885-891.
60. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017-1021.
61. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620-1628.
62. Millar EK, Dean JL, McNeil CM, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009;28(15):1812-1820.
63. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631-643.
64. Geradts J, Wilson PA. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 1996;149(1):15-20.
65. DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2014;(Dec):11.
66. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combinationwith letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
67. Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209-219.
68. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299(6):672-684.
69. Feldman DR, Patil S, Trinos MJ, et al. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2012;118(4):981-986.
70. Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res. 2001;61(10):4214-4221.
71. Noel EE, Yeste-Velasco M, Mao X, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176(6):2607-2615.
72. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci U S A. 1991;88(15):6662-6666.
73. Bartkova J, Lukas C, Sorensen CS, et al. Deregulation of the RB pathway in human testicular germ cell tumours. J Pathol. 2003;200(2):149-156.
74. Vaughn DJ, Gallagher M, Lal P, O'Dwyer P. Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors [abstract 4596]. J Clin Oncol. 2012; (suppl):4596.
75. Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91-95.